ColoScape™ / QuantiDNA™
Colorectal Cancer Screening
CommercialActive
Key Facts
About DiaCarta
DiaCarta is a commercial-stage diagnostics company with a focus on oncology and infectious diseases, utilizing its proprietary XNA and isobDNA™ technologies to enhance mutation detection sensitivity. Its product portfolio includes liquid biopsy tests for cancer therapy monitoring (RadTox™), colorectal cancer screening (ColoScape™), and bladder cancer detection (Oncuria®), alongside FDA-EUA infectious disease tests. The company has achieved significant commercial milestones, including Medicare coverage for RadTox™ and a statewide contract in Florida, supported by a CAP-accredited CLIA lab and global operations.
View full company profileTherapeutic Areas
Other Colorectal Cancer Screening Drugs
| Drug | Company | Phase |
|---|---|---|
| Shield (ECLIPSE Study) | Guardant Health | FDA Approved |
| Urine cfDNA Test for Colon Cancer Screening | JBS Science | Development |
| iFOB | Pangea Laboratory | Commercial |
| ColoHealth | New Day Diagnostics | Approved |
| CRC Screening Program | Polymedco | Commercial |
| SimpleScreen CRC | Freenome | Commercial (as LDT) |
| ColoSense | Geneoscopy | Approved |
| At-Home Colorectal Cancer Screening | SNT Biotech | Commercial |
| FIT System & Assay Development | Sentinel Diagnostics | Commercial |
| Next-Generation Cologuard® | Exact Sciences | Development |
| ColoAlert® | Mainz Biomed | Pivotal Trial |